170 related articles for article (PubMed ID: 36078937)
1. Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
Rymuza J; Gutowska K; Kurpios-Piec D; Struga M; Miśkiewicz P
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078937
[TBL] [Abstract][Full Text] [Related]
2. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.
Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P
Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547
[TBL] [Abstract][Full Text] [Related]
3. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
4. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
Pelewicz K; Miśkiewicz P
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38310626
[TBL] [Abstract][Full Text] [Related]
6. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
7. Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate.
Pelewicz K; Szewczyk S; Miśkiewicz P
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050327
[TBL] [Abstract][Full Text] [Related]
8. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
[TBL] [Abstract][Full Text] [Related]
9. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
10. Effect of methylprednisolone pulse therapy with and without alendronate on biochemical markers of bone turnover in patients with Graves' ophthalmopathy.
Gasińska T; Borowska A; Wichary H; Dec R
Pol Arch Med Wewn; 2012; 122(7-8):341-7. PubMed ID: 22728519
[TBL] [Abstract][Full Text] [Related]
11. Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.
Miśkiewicz P; Jankowska A; Brodzińska K; Milczarek-Banach J; Ambroziak U
Int J Endocrinol; 2018; 2018():1978590. PubMed ID: 30420883
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover decreases and bone structure improves during treatment with weekly high-dose methylprednisolone for 12 weeks in Graves' orbitopathy.
Harsløf T; Hikmet R; Ebbehøj E; Langdahl B
Endocrine; 2023 Dec; 82(3):664-672. PubMed ID: 37676399
[TBL] [Abstract][Full Text] [Related]
13. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
[TBL] [Abstract][Full Text] [Related]
14. Dysthyroid Optic Neuropathy: Treatment with Additional Intravenous Methylprednisolone Pulses after the Basic Schedule Is Associated with Stabilization or Further Improvement of Clinical Outcome.
Pelewicz M; Rymuza J; Pelewicz K; Miśkiewicz P
J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456161
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.
Censi S; Manso J; Pandolfo G; Franceschet G; Cavedon E; Zhu YH; Carducci S; Gomiero W; Plebani M; Zaninotto M; Watutantrige-Fernando S; Mian C; Camozzi V
J Endocrinol Invest; 2019 Jul; 42(7):859-865. PubMed ID: 30519958
[TBL] [Abstract][Full Text] [Related]
17. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
[TBL] [Abstract][Full Text] [Related]
18. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
20. [The influence of hyperthyroidism and glucocorticosteroid treatment on bone metabolism in patients with Graves' disease and ophthalmopathy].
Kaźmierczyk-Puchalska A; Kulig G; Krzyzanowska-Swiniarska B; Pilarska K
Endokrynol Pol; 2005; 56(3):259-64. PubMed ID: 16350719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]